GSK3β inactivation stabilizes β-catenin expression, induces its translocation to the nucleus, upregulates the downstream target CCND1 gene (encoding cyclin D1), and promotes breast cancer stem cell (BCSC) function and mammary tumor development9,10. The gene discussed is CCND1; the disease is breast carcinoma.